CAR T-cell Therapy in 2022: What You Need to Know Part II

Rayne H. Rouce, MD, BS, Texas Children’s Cancer Center for Cell and Gene Therapy, Houston, TX Recorded on April 8, 2022 Rayne H. Rouce, MD, BS Associate Professor Department of Pediatrics Texas Children’s Cancer Center for Cell and Gene Therapy Baylor College of Medicine Houston, TX As CAR T-cell therapy continues to evolve in new and exciting ways, new indications are approved and treatment toxicities reduced. In this episode, Dr. Rayne Rouce, from the Texas Children’s Cancer Center for Cell and Gene Therapy at Baylor College in Houston, joins us to discuss hot topics in CAR T-cell therapy, including how CAR-T has evolved over the past few years, understanding why some patients do better than others, access to treatment and overcoming logistics, shared care models with the referring physician, CAR-T in pediatric patients, communicating with patients, and so much more! This podcast episode is supported by Bristol Myers Squibb, CRISPR Therapeutics, Inc., Kite, a Gilead Company, Janssen Oncology & Legend Biotech, and Novartis Pharmaceuticals Corporation.